A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Trial details
- Registry ID
- NCT05548296
- Drugs studied
- ACR-368, Gemcitabine, OncoSignature
TrialRedline tracks 1 clinical trial sponsored by Acrivon Therapeutics: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296 | ACR-368, Gemcitabine, OncoSignature | Recruiting | 2027-05-30Estimated |
Names as written in the registry records.
NCT05548296 · Acrivon Therapeutics
Before: 401 participants (planned). After: 350 participants (planned).
NCT05548296 · Acrivon Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).. After: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers). Measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers)..
Before: 353 participants (planned). After: 401 participants (planned).
Before: 31 Oct 2026. After: 30 May 2027.